Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)

Brief summary (from the registry)

Drug therapy in patients with chronic low back pain is a major challenge for physicians. One of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient. Usually one of the classes of pain medication is given to patients with a similar clinical picture, although different pain mechanisms may be responsible for this clinical picture. Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason why an unique drug produces different responses (from a lacking analgesic effect up to excessive effect or side-effects. Quantitative sensory testing is a method that documents alterations in the pain perception system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for anticipation of drug efficacy.

Study details

Official title

Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain

Conditions

• Low Back Pain

Interventions

• Drug: Oxycodone 15mg
• Drug: Clobazam
• Drug: Imipramine
• Drug: Tolterodine

Sponsor

Insel Gruppe AG, University Hospital Bern

Collaborators

University of Bern; University of Zurich; Aalborg University

Start date

2010-07

Primary completion

2015-04

Sex

All

Age range

from 18 Years to 80 Years

Results posted

No results posted in this snapshot

Countries

Switzerland

Total sites listed

1

Eligibility criteria